AG-490 (Tyrphostin B42)

製品コードS1143 別名:Zinc02557947

AG-490 (Tyrphostin B42)化学構造

分子量(MW):294.30

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

サイズ 価格(税別)  
JPY 11620.00
JPY 8300.00
JPY 16600.00

カスタマーフィードバック(6)

  • Increased expression of VEGF and p-STAT3 induced by CXCL1 was blocked by either AG490 or SB225022 in AGS cells.

    Cancer Letters, 2015, 359(2): 335-43 . AG-490 (Tyrphostin B42) purchased from Selleck.

    Pre-treatment with AG490 and PD98059 alone or in combination leads to significant decrease in spheroid formation and number compared with PRL treatment alone.

    Carcinogenesis, 2014, 35(4): 795-806 . AG-490 (Tyrphostin B42) purchased from Selleck.

  • IL6 normally induces WASF3 expression in MDA231 cells, but co-treatments with AG490 (a pan-JAK inhibitor) show a dose-dependent reduction of both WASF3 levels and activated STAT3 levels.

    Carcinogenesis 2013 34, 1994-9. AG-490 (Tyrphostin B42) purchased from Selleck.

    Inhibition of JAK1/2 with AG490 or STAT3 with S3I-201 leads to reduced STAT3 activation and reduced WASF3 levels. In contrast, treatment with Dasatinib (SRC inhibitor) or Gefitinib (EGFR inhibitor) does not significantly affect activated STAT3 or WASF3 levels

    Carcinogenesis 2013 34, 1994-9. AG-490 (Tyrphostin B42) purchased from Selleck.

  • Prostate 2013 73(3), 267-77. AG-490 (Tyrphostin B42) purchased from Selleck.

    Biochem Biophys Res Commun 2013 435(4), 533-9. AG-490 (Tyrphostin B42) purchased from Selleck.

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
ターゲット
EGFR [1]
(Cell-free assay)
0.1 μM
体外試験

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. [1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. [2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. [3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. [4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210bcr-abl driven proliferation. [5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. [6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. [7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. [8]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BC3 MX7GeY5kfGmxbjDBd5NigQ>? MYexNFDjiIoEtV2= MXGyOEBp MoXGcYVlcWG2ZYOgVGVNKGOnbHygZZBweHSxc3nz NHqzXlQzPjF6NEm5PS=>
BCBL1 MmT0SpVv[3Srb36gRZN{[Xl? M1TyOlExOOLCidM1US=> MoPQNlQhcA>? NEjrcVBu\WSrYYTld{BRTUxiY3XscEBieG:ydH;zbZM> M1\zVlI3OTh2OUm5
BC3 Mn63SpVv[3Srb36gRZN{[Xl? Mn3tNVAx6oDLwsXN MVeyOEBp Mm\CcYVlcWG2ZYOg[IUueGixc4Doc5J6dGG2aX;uJI9nKFOWQWSzJINwenKnbHH0[YQhf2m2aDDIV3A4OCCjbnSgTHNHOSC{ZXT1Z5Rqd25? NXnEeHVGOjZzOES5PVk>
BCBL1 M2PSbWZ2dmO2aX;uJGF{e2G7 MYCxNFDjiIoEtV2= MVOyOEBp NGHYUolu\WSrYYTld{Bl\S2yaH;zdIhwenmuYYTpc44hd2ZiU2TBWFMh[2:{cnXsZZRm\CC5aYToJGhUWDdyIHHu[EBJW0Z{IILl[JVkfGmxbh?= NEnNNZozPjF6NEm5PS=>
BC3 NYWzU3FFTnWwY4Tpc44hSXO|YYm= MoTTNVAx6oDLwsXN M3i3c|I1KGh? NVXh[284cW6mdXPld{BiKGOxbYDs[ZRmKGG3dH;wbIFocWNiZnz1fOKh NGe1VHAzPjF6NEm5PS=>
BCBL1 NUTETolZTnWwY4Tpc44hSXO|YYm= NHLzN5gyODEkgJpCuW0> Ml7hNlQhcA>? M{fMVolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKG[udYlCpC=> NHzBcmgzPjF6NEm5PS=>
SK-MEL-28 MWfGeY5kfGmxbjDBd5NigQ>? MnLaOVAwOTBy4pEJxtVO M2L4TVQ5KGh? NGGyVpVFVVOR M{PjW5Jm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl MVeyOVIyPjV{Mh?=
MeWo MXLGeY5kfGmxbjDBd5NigQ>? MlfKOVAwOTBy4pEJxtVO M3f0RVQ5KGh? NHfRTXRFVVOR NFXKU45z\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=> Mnq0NlUzOTZ3MkK=
SK-MEL-5 MULGeY5kfGmxbjDBd5NigQ>? MVm1NE8yODEkgJpCuW0> NX\o[2dJPDhiaB?= MWHEUXNQ NXzUSIQyemWmdXPld{Bidm:ra3nzJJJme2m|dHHuZ4U> MVuyOVIyPjV{Mh?=
SK-MEL-2 MWXGeY5kfGmxbjDBd5NigQ>? MkTCOVAwOTBy4pEJxtVO M1nDb|Q5KGh? NEHEfGtFVVOR MXzy[YR2[2W|IHHuc4lscXNicnXzbZN1[W6lZR?= MlvGNlUzOTZ3MkK=
B16-F0 M3i0NWZ2dmO2aX;uJGF{e2G7 MUC1NE8yODEkgJpCuW0> MV[0PEBp NVfCeGZOTE2VTx?= NXHGTFhwemWmdXPld{Bidm:ra3nzJJJme2m|dHHuZ4U> MlTvNlUzOTZ3MkK=
TRPM2/HEK  NFXEcXlHfW6ldHnvckBCe3OjeR?= MUCwMlHjiJN{NdMgxtVO MonrNVXDqG2rbh?= NYn2XFBoTE2VTx?= NXrPN|RPemWmdXPld{BJOk9{LXnu[JVk\WRiQ3GyL4lv[3KnYYPlJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyMEBidmRidHjlJGlEPTEEoI\hcJVmKHejczCxMlfDqML3TR?= MnTqNlUyPzl3N{S=
U937  NXG5cXBSTnWwY4Tpc44hSXO|YYm= M2fFV|AvOeLCk{K1xsDDvU1? MkfCNVXDqG2rbh?= MWPEUXNQ MnmzdoVlfWOnczDINm8zNWmwZIXj[YQhS2F{K3nuZ5Jm[XOnIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{LDDhcoQhfGinIFnDOVDDqH[jbIXlJJdieyByLkVCpOK2VQ>? MWSyOVE4QTV5NB?=
TRPM2/HEK  MmXQSpVv[3Srb36gRZN{[Xl? NGnFNlIyOMLiwsXN M2HRXVQxyqCvaX6= MoG0SG1UVw>? MYLy[YR2[2W|IGTSVG0zKGGldHn2ZZRqd25iZY\lckBifCCqaXfoJINwdmOnboTyZZRqd26|IH;mJGgzVzJ? NXXqSHZLOjVzN{m1O|Q>
GL37  M3vGNWNmdGxiVnnhZoltcXS7IFHzd4F6 NEP1dZIxNTFywrFCuW0> M4jpVVQ5KGh? M2ThfJN2eHC{ZYPz[ZMhVGFiZYjwdoV{e2mxbh?= M{XmZlI1QTl7NkW3
NRK-52E NVjz[IpqTnWwY4Tpc44hSXO|YYm= MnfCNeKhyrWP NFnieZkyOCCvaX6= MmPqZoxw[2u|IITo[UB{fGmvdXzheI9zgSCnZn\lZ5Qhd2ZiQX7nJGlKKG:wIGDhfE0zKGW6cILld5Nqd28EoB?= NWr5b2V7OjR5MUC0NlM>
NRK-52E NGjhVlRHfW6ldHnvckBCe3OjeR?= NILrW5cyyqEEtV2= MnH5NVAhdWmw NYLMUGdW[myxY3vzJGFv\yCLSTDpcoR2[2WmIFPENlQh\XiycnXzd4lwdg>? NHvqcIIzPDdzMESyNy=>
HSC  NY\RSpZDTnWwY4Tpc44hSXO|YYm= MU[yNEDPxE1? MmfVNUBp MWLhZpJw\2G2ZYOgeIhmKGSrZn\ldoVvfGmjbDDl[oZm[3S|IH;mJIxmeHSrbjDvdkBCT0W| NVS0eIJKOjR4MUSxPVk>
EJ M1fqNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq1NE85OCEQvF2= MnfSNlQwPDhxN{KgbC=> NVrBT2lLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NUHUU3VROjR3OEewOFk>
EJ NFTiOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7HOVAwQDBizszN NFX3d5A1QCCq M2\FWINifXOnczDTMZBp[XOnIHHydoV{fA>? MUKyOFU5PzB2OR?=
EJ M4nKVmZ2dmO2aX;uJGF{e2G7 M4jPRlUxNzhyIN88US=> NUW0Om1OPDhiaB?= M{\KUIRwf26{ZXf1cIF1\XNiYz3NfYMtKGO7Y3zpcmQyNCC|dYL2bZZqdiCjbnSgWmVITiCneIDy[ZN{cW:wcx?= MVmyOFU5PzB2OR?=
HepG2 NHr2NZpHfW6ldHnvckBCe3OjeR?= M1vBRVUxNTVyMDFOwG0> NYjqdI1{PjEEoH3pci=> MVjpcohq[mm2czD0bIUhUUxvNj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSBqVInyO|A2MSCjbnSgV3RCXDNiKGT5dlcxPSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYjCdWxEOjR{NEKwOFY>
SGC7901 M2TTPGNmdGxiVnnhZoltcXS7IFHzd4F6 NV2xeJh1OC1zMECg{txO MXGyOE81QC95MjDo NFPmW45k[XW|ZYOgZUB{cWewaX\pZ4FvfCC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliZH;z[U1l\XCnbnTlcpRtgSCkdYSgco91KHSrbXWt[IVx\W6mZX70cJk> M3i5SFI1OTVzMkW1
AGS  NFWzOVNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXewMVExOCEQvF2= M1riXFI1NzR6L{eyJIg> NYHnPJN2[2G3c3XzJIEhe2mpbnnmbYNidnRicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHTvd4Uu\GWyZX7k[Y51dHliYoX0JI5wfCC2aX3lMYRmeGWwZHXueIx6 NXLOdZI5OjRzNUGyOVU>
SGC7901 NIXpWGpHfW6ldHnvckBCe3OjeR?= MljFOVAh|ryP NWXofFE5OjRxNEivO|IhcA>? M1HER5Rp\SCuZY\lcJMhd2ZicFrBT|Ih[mWpYX6geI8h\GWlbHnu[UBifCB{NDDodkwh[W6mIILlZo92dmSnZDDheEA4OiCqctMg M13GOFI1OTVzMkW1
AGS  NYS2RVB4TnWwY4Tpc44hSXO|YYm= NEHHPWU2OCEQvF2= Ml74NlQwPDhxN{KgbC=> MWL0bIUhdGW4ZXzzJI9nKHCMQVuyJIJm\2GwIITvJIRm[2yrbnWgZZQhOjRiaIKsJIFv\CC{ZXLveY5l\WRiYYSgO|IhcHMEoB?= NFnVWmkzPDF3MUK1OS=>
SGC7901 M33sbmZ2dmO2aX;uJGF{e2G7 M17STVUxKM7:TR?= NETGVmwzPC92OD:3NkBp M3vnd5Rp\SCleYTvdIxie22rYzDsc4NidGm8YYTpc44hd2ZicFrBT|IhMEqDS{KgdIhwe3Cqb4L5cIF1\WRiYYSgdoV{cWS3ZYOgWJlzOTByNzDhcoQhXHm{MUCwPEkh\GWlcnXhd4VlKGGodHXyJGFIPDlyIITy[YF1dWWwdDDmc5IhOjRiYX7kJFQ5KGi{LDDieZQhe3SjcoTl[EB1dyC{ZXLveY5lKGG2IEeyJIhz M1LHRVI1OTVzMkW1
AGS  MoPQSpVv[3Srb36gRZN{[Xl? MXW1NEDPxE1? NHi1VWUzPC92OD:3NkBp NVPTN2lvfGinIHP5eI9xdGG|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC|dHHyeIVlKHSxIILlZo92dmRiYYSgO|IhcHJ? MnP4NlQyPTF{NUW=
MC3T3-E1  M{HHNmZ2dmO2aX;uJGF{e2G7 NXuybW9qPTBizszN NXHMOZJiPCCq MU\pcohq[mm2czDIV2UucW6mdXPl[EBDVVB5IHHu[EBIUFJicILveIVqdiCneIDy[ZN{cW:wwrC= NWS4eItzOjN6N{e3N|Q>
7TD1-DXM NGnMV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D2TlExKM7:TR?= NUK3WoJGPzJiaB?= NInWendFVVOR NYTjW2R2cW6qaXLpeJMh[2WubDDndo94fGh? MkDWNlM5PzFzNUm=
7TD1-WD-90 NF\l[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK1NVAh|ryP M3LZXVczKGh? MmfHSG1UVw>? NUPMXod1cW6qaXLpeJMh[2WubDDndo94fGh? M2fhTlI{QDdzMUW5
7TD1-DXM MoDvRZBweHSxc3nzJGF{e2G7 MXW1NEDPxE1? MkPLOFghcA>? MUXEUXNQ MY\pcoR2[2W|IHHwc5B1d3Orcx?= NFXTe2MzOzh5MUG1PS=>
7TD1-WD-90 NGO0PG9CeG:ydH;zbZMhSXO|YYm= MlXROVAh|ryP NYPHcWF6PDhiaB?= MWjEUXNQ MlXxbY5lfWOnczDhdI9xfG:|aYO= MVmyN|g4OTF3OR?=
7TD1-WD-90  M3q1ZmZ2dmO2aX;uJGF{e2G7 MY[1NEDPxE1? Mki3OkBp MlO4SG1UVw>? MkDWd4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGpCUzJiYX7kJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMx?= M4jB[|I{QDdzMUW5
HepG2  NH7rTm1HfW6ldHnvckBCe3OjeR?= MX2xNFAh|ryP Moj2NVIwOjRiaB?= MVrpcohq[mm2czDTWGFVOyC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44> MXOyN|g{PjRyMB?=
RAW264.7  NWjyPGZ7TnWwY4Tpc44hSXO|YYm= M17kS|UxyqEQvF5CpC=> NV;ZdVViOjRxNEigbC=> MUjzeZBxemW|c3XzJHJCVkuOLXnu[JVk\WRib4P0[Y9kdGG|dH;n[Y5me2m| NWrzeFFmOjN4NkWwNVg>
RAW264.7 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXywMVUxyqEQvF5CpC=> MX60POKhcA>? NUO5OmFFcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[U1l\XCnbnTlcpRtgQ>? MlK2NlM3PjVyMUi=
RAW264.7 M{ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMVUxyqEQvF5CpC=> M1PVTFQ5yqCq MUTjZZV{\XNiYX6gZZJz\XO2IH;mJHJCXzJ4ND63JINmdGy|IHH0JJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?= M2DQU|I{PjZ3MEG4
RAW264.7 NVjMN4FkTnWwY4Tpc44hSXO|YYm= NVXPc5BIPTEEoN88US=> NWizSIFGOjRxNEigbC=> MWTpcohq[mm2czDSRW5MVC2rbnT1Z4VlKE6IQWTjNUBmgHC{ZYPzbY9vKGGwZDDwbI9{eGixconsZZRqd25ib3[gV4VzPzJ5U2TBWFM> MWSyN|Y3PTBzOB?=
A549  NF7OT4dHfW6ldHnvckBCe3OjeR?= M1rXdlIxNzRyIN88US=> M1zBXlIxKGh? NGDR[mszOCEQvF2gRWc1QTBic4XwdJJme3OnczD0bIUhemGmaXH0bY9vNWmwZIXj[YQhcW64YYPpc44hd2ZiQUW0PUBk\Wyucx?= M{DO[|I{PjJyMUmx
A549  MlnxSpVv[3Srb36gRZN{[Xl? MXmxNE8zOC92MDFOwG0> MUWyOEBp NG\zUZZ{fXCycnXzd4V{KHSqZTDyZYRq[XSrb36tbY5lfWOnZDDlcIV3[XSrb36gc4YhXkWJRtMg NU\peWhGOjN4MkCxPVE>
HUVECs MkDjR4VtdCCYaXHibYxqfHliQYPzZZk> MnnxNlAhyrWP M4HLflQhcA>? NHz2S4pifHSnboXheIV{KEh{T{KtbY5lfWOnZDDj[YxtKHOqcnnub4Fo\SCjbnSgbY1xem:4ZXSgeIhmKGG2dHHjbI1mdnRicnH0[UBw\iC2aHWgZ4VtdHN? M3P4XlI{PDh|OUS2
HUVECs NXWzZZFmSXCxcITvd4l{KEG|c3H5 NFX6[GMzOCEEtV2= NV\v[ZdrPCCq NHLDbYR{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUh[2WubDDhdI9xfG:2aXOgbY5l\Xh? M2nxPVI{PDh|OUS2
BV-2  NVvvWmtvTnWwY4Tpc44hSXO|YYm= NGrB[FAzOCEEtV2= MoLsNVYhcA>? MWLpcohq[mm2czDMVHMucW6mdXPl[EBUXEGWMTDwbI9{eGixconsZZRqd25id3n0bEBidG2xc4SgZ49ueGyndHXsfUBlcW2rbnnzbIVlKGmQT2Og[ZhxemW|c3nvci=> MnjwNlMzOzZ|N{C=
NRK-52E  M2nGXWZ2dmO2aX;uJGF{e2G7 NVG3V5FpPcLizszN NIrKU4c{OMLibXnu M3m0VoF1fGWwdXH0[ZMhSW6pLTix5qCUPylvaX7obYJqfGWmIGTHSk3PujFibWLORUBifCBzNtMgbOKh NIH2e3AzOzF5NEe1Oy=>
SW620  MnnTSpVv[3Srb36gRZN{[Xl? NHvxNJYzOCEEtV2= MnLZNU83KGh? MVLpcohq[mm2czDwMXNVSVR|IHHjeIl3[XSrb36= NGP6WGEzOzFzME[yOS=>
RPE  NFPWbnFHfW6ldHnvckBCe3OjeR?= NYrTe41YOzBiwsXNxsA> MV:zJIg> MXHpcohq[mm2czD0bIUhcW6mdXP0bY9vKG:oIICtV3RCXDNiZYjwdoV{e2mxbh?= M4fJUlI{ODl2ME[3
SW1116 MUHGeY5kfGmxbjDBd5NigQ>? M2rjOFExOCEEtV5CpC=> MnnHNlQwPDhxN{KgbC=> NH;ybGJl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhUkGNMjDhcoQheEqDS{KgeIlu\S2mZYDlcoRmdnSueR?= MlfKNlIxPTB5OUC=
HT29 NWm2eZRRTnWwY4Tpc44hSXO|YYm= NYDTN5UzOTByINM1UeKh NETwW2YzPC92OD:3NkBp M321W4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBLSUt{IHHu[EBxUkGNMjD0bY1mNWSncHXu[IVvfGy7 NYP1T|BNOjJyNUC3PVA>
SW1116 M3ztcWZ2dmO2aX;uJGF{e2G7 M4r0RVExOCEEtV5CpC=> M3zxUlI1NzR6L{eyJIg> NF:4c4pl\WO{ZXHz[ZMhfGinIIDTWGFVOyCuZY\lcJMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NYrXR3BJOjJyNUC3PVA>
HT29 NGLLNIhHfW6ldHnvckBCe3OjeR?= NGfmOI8yODBiwsXNxsA> NFHTe4wzPC92OD:3NkBp M3HSZoRm[3KnYYPld{B1cGVicGPURXQ{KGyndnXsd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh Ml;2NlIxPTB5OUC=
ARPE-19 NUDJNYdjTnWwY4Tpc44hSXO|YYm= NUnCfmlHPcLizszN NEXrfpk{OMLibXnu NUPhR2JncW6qaXLpeJMhUkGNMjDwbI9{eGixcnnsZZRqd25? MY[yNVYzODl4Mx?=
HSC-T6 MY\BdI9xfG:|aYOgRZN{[Xl? NHfT[2oyOMLizszN NVvFeXRnOsLiaNMg MkHrbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCxZjDIV2MuXDZiY3XscJMhcW6mdXPl[EBjgSCFRFW= MUGyNVM6Pjl7OB?=
HSC-T6 MYrGeY5kfGmxbjDBd5NigQ>? MXqxNOKh|ryP NFzsUmgzyqCqwrC= Mm\sbY5pcWKrdIOgeIhmKGW6cILld5Nqd26|IH;mJJB[NVOWQWSxJIFv\CCEYXSgbY5lfWOnZDDifUBETEV? MmLJNlE{QTZ7OUi=
Hep-2 Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPQNlUuOTByIN88US=> MnThNlQwPDhxN{KgbC=> M4DvNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M1XiWVIyOzB7NEix
Hep-2 MUDBdI9xfG:|aYOgRZN{[Xl? NFftb202OCEQvF2= M4XwNFI1NzR6L{eyJIg> NFX5PFBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IITpcYUh\GWyZX7k[Y51dHl? MV2yNVMxQTR6MR?=
Hep-2 MkHNSpVv[3Srb36gRZN{[Xl? NHjXcII2OCEQvF2= M2jKfFI1NzR6L{eyJIg> NIDxNFRqdmirYnn0d{BIOSC2bzDTJINmdGxiY4njcIUhfHKjboPpeIlwdiCjbnSgbY5lfWOnczDHNUBk\WyuIHP5Z4xmKGG{cnXzeC=> NUK1Rm95OjF|MEm0PFE>
Hep-2 NHzRdXlHfW6ldHnvckBCe3OjeR?= NY\LVWl[PTBizszN NUfBemRWOjRxNEivO|IhcA>? MoHJ[I94dnKnZ4XsZZRmeyC2aHWgV3RCXDNuIICtV3RCXDNiYX7kJJN2en[rdnnuJJBzd3SnaX6gcIV3\Wy| NF3qc44zOTNyOUS4NS=>
KF8 MmLOSpVv[3Srb36gRZN{[Xl? NYTUVnJnOTEEoN88UeKh MWixxsBp NYjZOFFITE2VT9Mg MXnpcohq[mm2czDJUE0{Oy2rbnT1Z4VlKE6ILd86RkBi[3SrdnH0bY9v NV3LcmlvOjB7NECwOFU>
KF8 M1G5S2Z2dmO2aX;uJGF{e2G7 NX;QPHg2OTEEoN88UeKh NHLvcYoyyqCqwrC= NGfKZWNFVVORwrC= M2\ZbolvcGmkaYTzJGlNNTN|LXnu[JVk\WRiSd86Ru6yKGSnZ4Lh[IF1cW:wIHHu[EBPTi4QulKgZYN1cX[jdHnvci=> NWfhZ3k6OjB7NECwOFU>
HEL  NXz1fWp4TnWwY4Tpc44hSXO|YYm= MlPaNVAxyqEQvF2= MnzvNVIuPzJiaB?= MX3pcohq[mm2czD0bIUhdGW4ZXygc4YheC2MQVuyMEBLSUt{ NUe4cY5UOjB4MkGwOlE>
HEL NFnn[|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;kb5ZpOTBywrFOwG0> NXTpXZhLOC13IHS= NELse|dz\WS3Y3XzJIdzd3e2aDDv[kBLSUt{Vk[xO2Yu\XiycnXzd4lv\yCKRVygZ4VtdHN? NUf3W3hROjB4MkGwOlE>
A-172 M1TWcmZ2dmO2aX;uJGF{e2G7 M1\CV|UxNzFyMNMg{txO MV20PEBp M374VJJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> NV7Zb4dQOjB3OEm1NlU>
MZ-18 MmDySpVv[3Srb36gRZN{[Xl? NUnpboFpPTBxMUCwxsDPxE1? M1H6c|Q5KGh? MU\y[YR2[2W|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M1PC[FIxPTh7NUK1
MZ-54 M1jQdmZ2dmO2aX;uJGF{e2G7 NF;CdYg2OC9zMEFCpO69VQ>? MX[0PEBp NX35co9nemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v NE\6UJozODV6OUWyOS=>
MZ-256 MVPGeY5kfGmxbjDBd5NigQ>? NFH3V442OC9zMEFCpO69VQ>? Ml3aOFghcA>? MnXUdoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u NVTvdWRNOjB3OEm1NlU>
MZ-304 NYTnXIcyTnWwY4Tpc44hSXO|YYm= MX[1NE8yODEEoN88US=> MkHmOFghcA>? MV;y[YR2[2W|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36= M1PES|IxPTh7NUK1
A-172 NYrrUVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7KOVAwOTBywrFOwG0> M1nwPFQ5KGh? M{SwNIxm[WS|IITvJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;2[ZIh[SC2aX3lJJBmemmxZDDv[kA1QMLiaB?= MVWyNFU5QTV{NR?=
MZ-18 M1fXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG5PZp5PTBxMUCwxsDPxE1? Ml\uOFghcA>? NVPhS4dLdGWjZIOgeI8h[SC|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo Mmr0NlA2QDl3MkW=
MZ-54 M4LCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPOWlZzPTBxMUCwxsDPxE1? M3LIU|Q5KGh? NIHCUoht\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi= MoWzNlA2QDl3MkW=
MZ-256 NV;ZNJVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nNT|UxNzFyMNMg{txO M2DwTlQ5KGh? NWX5dHQ3dGWjZIOgeI8h[SC|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo NYPHeGhQOjB3OEm1NlU>
MZ-304 M4DDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm1NE8yODEEoN88US=> NEXYUoQ1QCCq NFfLdJVt\WGmczD0c{BiKHO2YYTpd5Rq[2GubImgd4lodmmoaXPhcpQhemWmdXP0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDveoVzKGFidHnt[UBx\XKrb3Sgc4YhPDkEoHi= MUGyNFU5QTV{NR?=
A-172 M4P2dWZ2dmO2aX;uJGF{e2G7 MUS1NE8yODEEoN88US=> NILBbow1QCCq MXjpcohq[mm2czDtbYdz[XSrb36= NUPzU5JuOjB3OEm1NlU>
MZ-18 M4LoU2Z2dmO2aX;uJGF{e2G7 NFXHPXM2OC9zMEFCpO69VQ>? M4nmZVQ5KGh? NEXUSY5qdmirYnn0d{BucWe{YYTpc44> Mk[0NlA2QDl3MkW=
MZ-54 M2nCOGZ2dmO2aX;uJGF{e2G7 NWTke2gyPTBxMUCwxsDPxE1? MVy0PEBp MknWbY5pcWKrdIOgcYloemG2aX;u NHjrTm0zODV6OUWyOS=>
MZ-256 NXfQWnFzTnWwY4Tpc44hSXO|YYm= NIPpNIU2OC9zMEFCpO69VQ>? MXm0PEBp M3rxfolvcGmkaYTzJI1q\3KjdHnvci=> MUGyNFU5QTV{NR?=
MZ-304 NUfF[oV6TnWwY4Tpc44hSXO|YYm= NYn3O5pZPTBxMUCwxsDPxE1? MV:0PEBp MUXpcohq[mm2czDtbYdz[XSrb36= NGKwcpYzODV6OUWyOS=>
A-172 MXfGeY5kfGmxbjDBd5NigQ>? M{LGZlExOMLizszN NYXqTI04PDhiaB?= MYfpcohq[mm2czDpcpZie2mxbh?= NX\LN4VtOjB3OEm1NlU>
MZ-18 NEjVPZRHfW6ldHnvckBCe3OjeR?= MYWxNFDDqM7:TR?= MkGxOFghcA>? M2DabYlvcGmkaYTzJIlvfmG|aX;u NUPzdnpCOjB3OEm1NlU>
MZ-54 MXHGeY5kfGmxbjDBd5NigQ>? NXfafo9VOTBywrFOwG0> M1zmOFQ5KGh? M3jEdYlvcGmkaYTzJIlvfmG|aX;u MWWyNFU5QTV{NR?=
MZ-256 MmPCSpVv[3Srb36gRZN{[Xl? MUWxNFDDqM7:TR?= MXu0PEBp MYPpcohq[mm2czDpcpZie2mxbh?= M1:xNlIxPTh7NUK1
MZ-304 MWHGeY5kfGmxbjDBd5NigQ>? M1ThPVExOMLizszN MWe0PEBp NFrnR2RqdmirYnn0d{Bqdn[jc3nvci=> Mme3NlA2QDl3MkW=
A-172 NYjOSWhCTnWwY4Tpc44hSXO|YYm= M372OFUxNzFyMNMg{txO MVq0PEBp MXny[YR2[2W|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz MXeyNFU5QTV{NR?=
MZ-18 M1i5[2Z2dmO2aX;uJGF{e2G7 M1\UN|UxNzFyMNMg{txO NWfS[XNNPDhiaB?= M3LDeJJm\HWlZYOgeJJidnOlcnnweIlwdiCxZjDNUXAh\2WwZYOgZY5lKHKnZIXj[ZMh\W68eX3heIlkKGGldHn2bZR6KG:oIF3NVJM> NIPMcVEzODV6OUWyOS=>
MZ-54 MnjWSpVv[3Srb36gRZN{[Xl? Mo[xOVAwOTBywrFOwG0> MkPTOFghcA>? M3PtWpJm\HWlZYOgeJJidnOlcnnweIlwdiCxZjDNUXAh\2WwZYOgZY5lKHKnZIXj[ZMh\W68eX3heIlkKGGldHn2bZR6KG:oIF3NVJM> MYqyNFU5QTV{NR?=
MZ-256 NF:3[IZHfW6ldHnvckBCe3OjeR?= MmXPOVAwOTBywrFOwG0> NXHHSINvPDhiaB?= NUHqS3Q5emWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>? M4fTTlIxPTh7NUK1
MZ-304 Mk\mSpVv[3Srb36gRZN{[Xl? NGnMSlI2OC9zMEFCpO69VQ>? Mn73OFghcA>? NWXW[nRxemWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>? M3jvNVIxPTh7NUK1
SW1990 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzXfYszOCEQvF2= MVqyOE81QC95MjDo Mn62bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> MYqyNFQ5Ojh3OB?=
SW1990 NEnycmRHfW6ldHnvckBCe3OjeR?= NVzNfYNDOjBizszN NFfTN3ozPCCq NUHTNnZi\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE2PUD2yJIFv\CCYRVfGJI1TVkG| NVW1OnZCOjB2OEK4OVg>
SW1990 MVfGeY5kfGmxbjDBd5NigQ>? NFG3d2MzOCEQvF2= NH[wVmczPCCq MlzG[IVkemWjc3XzJJRp\SCrboTlcpNqfHlib3[gdE1UfGG2MzDlfJBz\XO|aX;u NEn3ZXEzODR6Mki1PC=>
SW1990 NIrVdFVKdn[jc3nvckBCe3OjeR?= NFHiZZczOCEQvF2= NYT3N5oyOjRiaB?= MlzzdoVlfWOnczDpcpZie2mxbjDv[kBUXzF7OUCgZ4VtdHQEoB?= MYGyNFQ5Ojh3OB?=
THP1 MWLGeY5kfGmxbjDBd5NigQ>? M37HO|ExKHWP MV6zNEBucW8EoB?= NWTtN5BvcW6qaXLpeJMhW1SDVEOgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wIHL5JI93\XJiNkCl M17CRVIxOzl|Nkmw
BMMC M1WwNWZ2dmO2aX;uJGF{e2G7 NWrEVHpZOC1zMDFOwG0> Mn3WNVXDqG2rbh?= M2O1OIlvcGmkaYTzJGxVSzUEoILlcIVie2ViaX6gZUBld3OnLXTldIVv\GWwdDDmZZNpcW:wIIfpeIghdmWjcjDjc41xdGW2ZTDpcohq[mm2aX;uJIF1KGOxbnPlcpRz[XSrb37zJQKqxjFywrFOwG0> MX6xPVg{PTh2NR?=
A549 NIDtVmdHfW6ldHnvckBCe3OjeR?= NV;oV|F4OTVizszt MUexJIg> NF;CeFlqdmirYnn0d{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIGPURXQyKG:wIIT5do9{cW6nIEewNUB4[XNiZHX0[YN1\WRiMUWgcYlvKGGodHXyJHNRTSCEIITy[YF1dWWwdB?= MU[xPVgxOTZ4NR?=
OVCAR-3 MWXGeY5kfGmxbjDBd5NigQ>? MW[xNEB2VQ>? NVTVTohJOSCq MlXabY5pcWKrdIOgUHBCNWmwZIXj[YQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w MVSxPVY1PzN4Mx?=
PA-1 MYHGeY5kfGmxbjDBd5NigQ>? M1HFZVExKHWP NUHQdHozOSCq MX;pcohq[mm2czDMVGEucW6mdXPl[EBUXEGWMzDwbI9{eGixconsZZRqd25? NYfkW4w6OTl4NEezOlM>
OVCAR-3 M1jVOWZ2dmO2aX;uJGF{e2G7 NEfzSpAyOCC3TR?= MVWxJIg> NV7pZmlYcW6qaXLpeJMhKEySQT3pcoR2[2WmIH;2ZZJq[W5iY3HuZ4VzKGOnbHygcY91cWyrdIm= NWnJd|E5OTl4NEezOlM>
PA-1 NFnoVW1HfW6ldHnvckBCe3OjeR?= NYjBNlVlOTBidV2= MXmxJIg> NXKyOGo4cW6qaXLpeJMhKEySQT3pcoR2[2WmIH;2ZZJq[W5iY3HuZ4VzKGOnbHygcY91cWyrdIm= NV3WN5o2OTl4NEezOlM>
Jurkat  NFixS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC1NEDPxE1? Mnv5NlQwPDhxN{KgbC=> MorY[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIdzd3e2aDDpcohq[mm2aX;u M4\Lc|E6PTZ2OEmx
SUPT1  NELBd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:1NEDPxE1? MXGyOE81QC95MjDo NWfrU4V5\W6qYX7j[ZMhXFKDSVytbY5lfWOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9v M{e0elE6PTZ2OEmx
Jurkat  NFnpNo9CeG:ydH;zbZMhSXO|YYm= MVK1NEDPxE1? MUCyOE81QCCq NI\JWFBmdmijbnPld{BVWkGLTD3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NH\NV4UyQTV4NEi5NS=>
SUPT1  MW\BdI9xfG:|aYOgRZN{[Xl? NIDnUoo2OCEQvF2= NVHDNZIyOjRxNEigbC=> MnvS[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIFxd3C2b4Ppdy=> M1rlXVE6PTZ2OEmx

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Administration of AG-490 drastically reduces the numbers of CD45+ and HLA-DR+ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. [2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. [6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. [8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. [6]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro kinase autophosphorylation:

AG-490 is dissolved in DMSO 10%-H2O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M8Ac2, 2 mM MnCl2, 1 mM NaVO3, 1 μM ATP, and 1 μCi[γ-32P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
細胞試験:

[2]

+ 展開
  • 細胞株: Pre-B ALL
  • 濃度: Dissolved in DMSO, final concentrations ~ 50 μM
  • 反応時間: 16 hours
  • 実験の流れ:

    Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [3H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter.


    (参考用のみ)
動物試験:

[2]

+ 展開
  • 動物モデル: SCID mice intravenously injected with ALL cells
  • 製剤: Dissolved in DMSO
  • 投薬量: 0.85 mg + 0.5 mg daily
  • 投与方法: Continuous pump infusion supplemented with daily intraperitoneal injections
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 58 mg/mL (197.07 mM)
Ethanol 6 mg/mL (20.38 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+45% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 294.30
化学式

C17H14N2O3

CAS No. 133550-30-8
保管
in solvent
別名 Zinc02557947

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?

  • 回答:

    AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFRシグナル伝達経路

EGFR Inhibitors with Unique Features

相関EGFR製品

Tags: AG-490 (Tyrphostin B42)を買う | AG-490 (Tyrphostin B42) ic50 | AG-490 (Tyrphostin B42)供給者 | AG-490 (Tyrphostin B42)を購入する | AG-490 (Tyrphostin B42)費用 | AG-490 (Tyrphostin B42)生産者 | オーダーAG-490 (Tyrphostin B42) | AG-490 (Tyrphostin B42)化学構造 | AG-490 (Tyrphostin B42)分子量 | AG-490 (Tyrphostin B42)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID